Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $97.50 USD
Change Today -3.50 / -3.47%
Volume 940.7K
INCY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

incyte corp (INCY) Snapshot

Open
$100.36
Previous Close
$101.00
Day High
$100.81
Day Low
$97.21
52 Week High
04/22/15 - $111.93
52 Week Low
10/13/14 - $43.86
Market Cap
17.5B
Average Volume 10 Days
1.4M
EPS TTM
$-0.22
Shares Outstanding
179.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INCYTE CORP (INCY)

incyte corp (INCY) Related Businessweek News

No Related Businessweek News Found

incyte corp (INCY) Details

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, which is in Phase III clinical trial for pancreatic cancer; and in Phase II trial for the treatment of breast cancer, non-small cell lung cancer, and colorectal cancer, as well as INCB39110 that is in Phase I/II trial for malignancies; and in Phase II trial for non-small cell lung cancer. The company’s product pipeline also comprises INCB52793, which is in Phase I/II clinical trial for the treatment of B-lymphoid malignancies; INCB50465 that is in Phase I/II clinical trial for hematology/oncology; and INCB39110+INCB40093, which is in Phase I/II trial for B-lymphoid malignancies. In addition, it is developing epacadostat that is in Phase II clinical trial for metastatic melanoma, as well as in Phase I/II trial for non-small cell lung cancer and various tumor types; and capmatinib, which is in Phase I/II clinical trial for the treatment of solid tumors, as well as in Phase II trial for hepatocellular carcinoma and non-small cell lung cancer. Further, the company is developing INCB54828 that is in Phase I/II clinical trial for the treatment of solid tumors; INCB54329, which is in Phase I/II clinical trial for the treatment of hematology/oncology; and baricitinib that is in Phase III trial for rheumatoid arthritis, as well as in Phase IIb clinical trial for psoriasis, and Phase II trial for diabetic nephropathy. It has a collaboration and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

588 Employees
Last Reported Date: 02/17/15
Founded in 1991

incyte corp (INCY) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $2.9M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $113.8K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $521.0K
Chief Drug Development Officer and Executive ...
Total Annual Compensation: $403.0K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $365.6K
Compensation as of Fiscal Year 2014.

incyte corp (INCY) Key Developments

Incyte Corporation Announces Management Changes

Effective May 4, 2015, the board of directors of Incyte Corporation appointed Paul Trower, age 45, as the company’s Vice President, Finance and Principal Accounting Officer. Mr. Trower joined the company in April 2004 as Director of Financial Reporting, and has held roles of increasing responsibility, most recently as Vice President and Controller. Mr. Trower succeeds Laurent Chardonnet as the company’s principal accounting officer. Mr. Chardonnet will be assuming new responsibilities with the company’s European operations.

Incyte Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Incyte Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, total revenue was $159.275 million against $89.792 million a year ago. Loss from operations was $6.935 million against $22.935 million a year ago. Loss before income taxes was $17.992 million against $33.908 million a year ago. Net loss was $18.359 million or $0.11 per basic and diluted share against $33.957 million or $0.21 per basic and diluted share a year ago.

Incyte Corporation to Report Q1, 2015 Results on Apr 30, 2015

Incyte Corporation announced that they will report Q1, 2015 results at 8:00 AM, US Eastern Standard Time on Apr 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INCY:US $97.50 USD -3.50

INCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $55.74 USD -1.87
ARIAD Pharmaceuticals Inc $8.99 USD -0.25
BioMarin Pharmaceutical Inc $113.92 USD -2.40
Jazz Pharmaceuticals PLC $176.42 USD -6.81
Vertex Pharmaceuticals Inc $122.15 USD -4.15
View Industry Companies
 

Industry Analysis

INCY

Industry Average

Valuation INCY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 29.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit www.incyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.